Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptides corresponding to residues 2-13 and 107-120 of human Bcl-3.|
|Storage buffer||PBS with 0.05% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Western Blot (WB)||0.5-1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: Jurkat whole cell lysate.
NF-kB is silenced in the cytoplasm by an inhibitory protein, IkB (1). The proto-oncoprotein Bcl-3 is a member of the IkB family and is present predominantly in the nucleus. IkBa and Bcl-3 are similar in the central ankyrin repeat domains, where as they differ at the N- and –C terminus. These differences may explain the differential binding of IkBa and Bcl-3. Two molecules of Bcl-3 can associate with NF-kB, where as only one molecule of IkBa bind to NF-kB. BCL-3 mRNA and protein expression are induced by NF-kB-activating agents. Down-regulation of BCL-3 induction results in prolonged, enhanced NF-kB binding and increased NF-kB-dependent transcription. Several cytokines, such as, TNFa or IL-1b, and mitogens as phorbolester (PMA) trigger rapid formation of Bcl-3-p50 complexes with the same kinetics as activation of p50-p65 complexes.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
B-cell leukemia/lymphoma 3; B-cell lymphoma 3-encoded protein; BCL-3; BCL4; chronic lymphatic leukemia protein; D19S37; proto-oncogene BCL3
BCL3; BCL4; D19S37